Secukinumab versus ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real‐world practice

Abstract

A descriptive retrospective, study comparing the first 29 patients who received ustekinumab at our unit following its approval in September 2009 with 30 patients who received secukinumab after its marketing in Spain in November 2015 was conducted. The secukinumab treatment group showed higher whitening rates and a higher percentage of patients reached a psoriasis area and severity index (PASI) 75 response (89.65 vs. 73.33%, p = .108) than those in the ustekinumab treatment group at Week 52. The number of patients achieving a PASI 90 response was particularly remarkable and statistically significant (82.75 vs. 43.33%, p = .002). Better PASI 75 response rates were also observed in the secukinumab group than in the ustekinumab group after 52 weeks in biologic‐naïve patients (89 vs. 72%, p = .586) and among those previously treated with one line (92 vs. 100%, p = 1.00) or with two or more previous biologic lines (88 vs. 62%, p = .336). These differences were greater in the number of patients reaching a PASI 90 response in the secukinumab group than in the ustekinumab group in biologic‐naïve patients (78 vs. 63%, p = .642) and in those previously treated with one (92 vs. 50%, p = .083) or with two or more treatment lines (75 vs. 31%, p = .080). These regular‐practice results overlap or surpass those obtained in the CLEAR clinical trial.

Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate‐to‐severe psoriasis after 1 year of treatment: Real‐world practice

“…Given that it is increasingly common to find patients who have already presented failure to prior biologic treatments, we believe that it is of interest to study the response profile of secukinumab and ixekizumab in these situations. In our study, as in others published in the literature, a decrease in efficacy is seen as the number of prior biologics increases, compared to those bio‐naïve patients, in which efficacy is greater . Once again, both therapies shared a similar PASI 100 response in all subgroups and ixekizumab tended to achieve a higher PASI 75 and 90 response, especially in those patients with 2 or more prior biologics (PASI 75 response of 54.5% vs 100.0%, P = .039).…”

Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY)

“…Results from these studies support secukinumab as an effective option for long‐term treatment of moderate to severe psoriasis. Moreover, secukinumab has shown superior efficacy in the real world compared with ustekinumab as determined by PASI 90 after 1 year; this difference was significant regardless of previous exposure of patients to biologics 35 …”

Ixekizumab vs ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real‐world practice

“…Data are also available from studies conducted in daily clinical practice, 29‐33 being remarkable the one carried out by Elberdin et al with a follow‐up of 61 patients treated with ustekinumab over 8 years, in which 37/61 (60.6%) achieved a PASI 75 response at 12 months, and 36/61 (59%) a PASI 90 response.…”